1	Association of mid-age Life's Essential 8 score with digital cognitive performance
2	and incident Alzheimer's disease: the Framingham Heart Study
3	Running title: mid-age Life's Essential 8 score with digital cognitive performance
4	
5	Jian <b>Yang</b> , MPH <sup>1,*</sup> ; Huitong <b>Ding</b> , PhD <sup>2,3,*</sup> ; Yi <b>Li</b> , MA <sup>1</sup> ; Ting Fang Alvin <b>Ang</b> , MD,
6	MPH <sup>2,3,4</sup> ; Sherral <b>Devine</b> , PhD <sup>2,3</sup> ; Yulin <b>Liu</b> , MS <sup>2,3</sup> ; Wendy <b>Qiu</b> , MD, PhD <sup>2</sup> ; Rhoda <b>Au</b> ,
7	PhD <sup>2,3,4,5,6</sup> ; Jiantao <b>Ma</b> , PhD <sup>7</sup> ; Chunyu <b>Liu</b> , PhD <sup>1,#</sup>
8	
9 10	<sup>1</sup> Department of Biostatistics, Boston University School of Public Health, Boston, MA, 02118, USA
11 12	<sup>2</sup> Department of Anatomy and Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA
13 14	<sup>3</sup> Framingham Heart Study, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA
15 16	<sup>4</sup> Slone Epidemiology Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA
17 18	<sup>5</sup> Department of Neurology and Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA
19 20	<sup>6</sup> Department of Epidemiology, Boston University School of Public Health, Boston, MA, 02118, USA
21 22 22	<sup>7</sup> Division of Nutrition Epidemiology and Data Science, Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, 02111, USA
23	
24	I nese authors contribute equally
25 26 27 28 29	#Address for Correspondence: Chunyu Liu, PhD; <u>liuc@bu.edu</u> Crosstown Building 801, Massachusetts Avenue Boston, MA 02118, USA.
30	
31	

## 32 ABSTRACT

- 33 Background: Emerging studies indicate that cardiovascular health (CVH) is a
- 34 modifiable risk factor for AD. However, studies on how mid-life Life's Essential 8 (LE8)
- 35 scores affect the AD risk and digital cognitive performance are limited.
- 36 **Objective**: To examine the associations between CVH in middle age, as defined by LE8
- 37 scores, and subsequent digital cognitive performance and incident AD.
- 38 **Methods**: Linear regression and Cox proportional-hazard models were used to examine
- 39 the associations of mid-age CVH with dCDT performance and incident AD, respectively.
- 40 Prediction performance of mid-age LE8 scores for incident AD were assessed using
- 41 ROC curve analysis.
- 42 **Results**: Every one-SD increase in mid-age LE8 total score was associated with a 0.16-
- 43 SD increase in dCDT total score (p < 0.001). Ideal CVH in middle age was associated
- 44 with higher dCDT scores compared to intermediate CVH. Furthermore, higher mid-age
- 45 LE8 scores were associated to a decreased risk of AD, with ideal CVH significantly
- 46 lowering AD risk compared to intermediate CVH. The combination of dCDT
- 47 performance, mid-age LE8 scores, APOE ε4 status, and other covariates provided the
- 48 best prediction performance for incident AD, with an AUC of 0.84. Notably, mid-life LE8
- 49 scores improved its predictive accuracy by 5.7%.
- 50 **Conclusion:** Our findings emphasize the critical role of CVH in middle age as a
- 51 predictor of both digital cognitive performance and the risk of developing AD,
- 52 highlighting the importance of early intervention on CVH to delay the progression of
- 53 cognitive decline.

## 54 Key Words: Life's Essential 8, Cardiovascular health, Digital cognitive performance,

## 55 Alzheimer's disease

### 56 **INTRODUCTION**

57 Alzheimer's disease (AD) poses a significant challenge to public health due to its 58 gradual onset and the progressive deterioration of cognitive functions [1]. With effective 59 treatments for AD being scarce, the focus has shifted towards early detection as a key 60 strategy for managing the disease [2]. Studies highlight the importance of mitigating 61 major risk factors, particularly cardiovascular health (CVH), during middle age before cognitive decline begins, to lower AD risk [3-6]. The American Heart Association (AHA) 62 63 has put forward Life's Simple 7 (LS7) as a CVH metric targeting modifiable risk factors 64 including blood pressure, blood sugar, cholesterol levels, body mass index (BMI), 65 physical activity, diet, and smoking [7]. Many studies have reported a significant 66 association between higher LS7 scores and decreased AD risk [8-10]. Building on LS7, 67 the AHA has recently introduced Life's Essential 8 (LE8), refining the model to 68 incorporate sleep quality and a 0 to 100 scale for a more precise CVH quantification [11]. 69 Despite this, the effect of mid-life LE8 scores on cognitive health and their influence on 70 AD risk remains an underexplored area.

71 Understanding the association between mid-life LE8 scores and early cognitive 72 decline requires accurate tracking of these initial subtle cognitive changes. Advances in 73 technology have led to the development of precise digital methods for cognitive function 74 assessment, significantly surpassing traditional neuropsychological (NP) tests in terms 75 of objectivity and sensitivity to early signs of cognitive decline. The digital Clock Drawing 76 Test (dCDT) exemplifies such innovation by employing a digitizing ballpoint pen and 77 grid-patterned paper to replicate the conventional clock drawing test [12]. This approach 78 utilizes advanced software to track pen movements, thus refining CDT and NP

79 evaluations with standardized administration, objective scoring, and reduced biases. 80 Additionally, dCDT covers a broad spectrum of cognitive domains and utilizes a 81 comprehensive scoring system for an in-depth analysis of cognitive abilities [12, 13]. 82 Therefore, determining the association between mid-life CVH, as indicated by LE8 83 scores, and dCDT's capacity for early cognitive assessment is essential for timely 84 intervention strategies. 85 The objective of this study was to investigate associations of mid-age LE8 scores with dCDT and incident AD in the Framingham Heart Study (FHS), aiming to offer 86 87 essential insights for the prevention of cognitive decline. 88 89 **METHODS** Study population 90 91 The FHS, established in 1948, is a community-based cohort study [14]. The Offspring 92 Cohort of the FHS began in 1971, registering 5,124 individuals, including children of the 93 Original Cohort and their spouses. These participants are subject to routine health 94 examinations roughly every four years, with ten such examinations conducted so far, 95 during which a broad array of health data is gathered [15, 16]. 96 This study included 1,413 participants from the FHS Offspring Cohort, each of 97 whom had participated in at least one dCDT since 2011 and had been involved in at 98 least one of the FHS core exams from 5 to 9 (1991-2014). Exclusions were made for participants under 60 years of age (n=67) and those diagnosed with non-AD dementia 99

100 (n=25) at the time of dCDT. An additional 123 participants were excluded from the study

101	due to incomplete data on independent and outcome variables, as well as covariates,
102	resulting in a refined cohort of 1,198 individuals eligible for subsequent analysis
103	(Supplementary Figure 1).
104	Construction of mid-age LE8 score
105	We defined "middle age" as the age range of 45 to 65 years across exams 5-9 [17-19],
106	due to the measurement of most LE8 components starting from exam 5. Considering
107	participants might have undergone multiple examinations in this period, the average
108	LE8 scores were calculated for these participants from exams 5-9.
109	The LE8 total score was derived based on the AHA guidelines [11], with
110	modifications made to fit the FHS cohorts [20]. Briefly, individuals who quit smoking less
111	than two years ago were given a score of 25 for smoking. The Dietary Approaches to
112	Stop Hypertension (DASH) [21] diet score was calculated based on components
113	including the intake of vegetables, fruits, nuts, legumes, and whole grains; as well as
114	low-fat dairy, and the intake of red and processed meat, sugar-sweetened beverages,
115	and sodium [22]. The physical activity score was computed by considering the duration
116	and strength of activities including sleep, sedentary, and different strengths of activities
117	(i.e. light, moderate, and vigorous) [23]. The other scores such as sleep quality, blood
118	sugar levels, BMI, blood lipid, blood pressure were derived based on the standard of
119	AHA [11]. We calculated the mid-age LE8 total score by averaging scores across all
120	eight LE8 components. Additionally, two sub-scores, LE8 health behavior score and
121	LE8 health factor score, were also obtained[11]. Furthermore, we classified the mid-age
122	LE8 total score into three CVH categories: Poor-CVH (LE8 total score below 50),

Intermediate-CVH (LE8 total score between 50 and 70), and Ideal-CVH (LE8 total score
above 70) [11].

## 125 **Construction of dCDT scores**

- 126 The details of the dCDT can be found in previous studies [12, 13, 24-26]. This study
- 127 used the dCDT total score, and eight domain-specific scores including COM/COP
- 128 Drawing Efficiency scores, COM/COP Simple Motor scores, COM/COP Information
- 129 Processing scores, and COM/COP Spatial Reasoning scores.

### 130 Diagnostic criteria of Alzheimer's disease

- 131 The cognitive status of FHS participants has been consistently monitored using a
- 132 variety of methods, including periodic assessments with the NP test battery [6, 27, 28].
- 133 To ensure accurate diagnoses, a dedicated team comprising neurologists and
- 134 neuropsychologists reviewed all available information. This team reaches a consensus
- 135 on whether participants meet the Diagnostic and Statistical Manual of Mental Disorders,
- 136 4th edition (DSM-IV) criteria for dementia and assigns specific subtype diagnoses as
- 137 needed [29]. The diagnostic criteria for AD adhere to the National Institute of
- 138 Neurological and Communicative Disorders and Stroke and the AD and Related
- 139 Disorders Association [30].

### 140 **Covariates**

- 141 Covariates included age at dCDT examination, delta age, sex, education levels,
- 142 apolipoprotein-E (APOE) genotype. The delta age was calculated to show the difference
- 143 in years between participants' age at dCDT and their age at the most recent
- 144 examination that established their mid-life period. Participants with APOE  $\varepsilon 2/\varepsilon 4$  allele

were excluded. The remaining participants were stratified into two groups based on the presence ( $\epsilon 3/\epsilon 4$  and  $\epsilon 4/\epsilon 4$ ) or absence ( $\epsilon 2/\epsilon 3$ ,  $\epsilon 2/\epsilon 2$  and  $\epsilon 3/\epsilon 3$ ) of the  $\epsilon 4$  allele.

#### 147 Statistical analysis

LE8 scores and dCDT scores were converted to z-scores. Linear regression models were used to examine the associations of dCDT total score with LE8 total score and CVH categories. Furthermore, the pairwise associations between LE8 sub-scores and dCDT sub-scores were analyzed by linear regression models (**Figure 1**). All models were adjusted for age at dCDT, sex, education level, and delta age. The multiple comparisons were adjusted by the false discovery rate (FDR) correction [31].

Sex-specific analysis was performed to assess the variance in the effect size of the association between mid-age CVH and dCDT total score. Stratified analysis was further applied in *APOE*  $\varepsilon$ 4 allele carriers and non-carriers. To determine whether sex and the presence of *APOE*  $\varepsilon$ 4 allele modify the association between mid-age CVH and dCDT performance, we conducted additional analyses that include interaction terms (sex\*CVH categories) and (*APOE*  $\varepsilon$ 4 status\*CVH categories) in the regression models, respectively.

161 Cox Proportional-Hazard model was used to examine the association between 162 mid-age LE8 total score and incident AD. Adjustments were made for age at the time of 163 the last FHS examination during middle age, sex, and education level (**Figure 1**). The 164 follow-up period was determined from the end of middle age to the earliest occurrence 165 of AD onset, death, or up to July 12, 2023. Additionally, we applied the Cox model using

the categorical variable of mid-age CVH as the main predictor, while adjusting for thecovariates.

168	The association between dCDT performance and incident AD was examined by
169	Cox model with dCDT total score as primary predictor and AD incidence as the
170	dependent outcome (Figure 1). The covariates included age at dCDT, sex, and
171	education level. Follow-up time spanned from the dCDT assessment to the earliest
172	occurrence of AD onset, death, or July 12, 2023. In the secondary analysis, we
173	conducted Cox model with the eight dCDT subdomain scores as main predictors and
174	AD onset as outcome, adjusting for the same set of covariates. We tested the
175	proportional hazard assumption in all Cox models using the Schoenfeld residuals test.
176	We evaluated the predictive ability of the mid-age LE8 total score, dCDT total
177	score, and various covariates for AD risk by constructing five logistic regression models
178	and comparing their area under the receiver operating characteristic (ROC) curve
179	(AUC). The baseline model included covariates with age, sex, and education level.
180	Three subsequent models incorporated the following additional variables one at a time:
181	mid-age LE8 total score, dCDT total score, and APOE ε4 status. The final
182	comprehensive model encompassed age, sex, education level, mid-age LE8 total score
183	dCDT total score, and APOE £4 status. All analysis were performed using RStudio
184	version 4.2.1.

#### 185 **RESULTS**

#### **186 Participant characteristics**

187 This study included 1,198 participants (mean age at dCDT measurement 73±7, 56.8%

- 188 women, 47.5% college and higher). Forty-five participants were diagnosed with AD
- during the median of 17.5 years follow up. The detailed clinical characteristics were
- 190 shown in **Table 1**.

#### 191 Association of demographic variables with mid-age LE8 scores and dCDT scores

- 192 In the univariate analysis, with each additional year of age, participants' dCDT total
- 193 scores decreased by 0.07 SD (95% CI: -0.08, -0.06; *P*<0.001), indicating a decline in
- 194 cognitive performance with age (**Supplementary Table 1**). Women demonstrated
- superior cognitive performance than men, scoring on average 0.19 SD (95% CI: 0.03,
- 196 0.36) higher on the dCDT total scores (*P*=0.02). Additionally, a clear educational
- 197 gradient was observed in dCDT performance. No significant association was observed
- 198 between education level and mid-age LE8 total score in the study participants
- 199 (Supplementary Table 2).

### 200 Association between mid-age LE8 scores and dCDT scores

201 An increase of one SD in the mid-life LE8 total score was positively associated with a

- 202 0.16 SD increase in the dCDT total score (95% CI: 0.06, 0.24; *P*<0.001) (**Figure 2**).
- 203 When using participants with intermediate CVH as a reference group, those within the
- ideal CVH showed a statistically significant increase of 0.18 SD in their dCDT total
- scores (95% CI: 0.01, 0.34; *P*=0.036). In contrast, those categorized with poor CVH had

206	an average decrease of 0.36 SD in their dCDT total scores (95% CI: -0.67, -0.05;
207	<i>P</i> =0.024) ( <b>Table 2</b> ).
208	Higher LE8 total score were associated with enhanced dCDT performance
209	(Supplementary Figure 2). The LE8 total score was significantly associated with most
210	dCDT sub-scores (FDR-adjusted $P \le 0.03$ ), except for the scores of drawing efficiency
211	and information processing under the command task. Compared to the LE8 health
212	behavior score, the LE8 health factor score showed significant association with more
213	dCDT sub-scores (4 versus 6) (Supplementary Figure 2).
214	Effect modification by sex
215	An increase of one SD in the mid-life LE8 total score was significantly associated with a
216	0.20-SD increase in the dCDT total score among women (95% CI: 0.10, 0.30; P<0.001)
217	(Supplementary Table 3). For men, this association did not achieve statistical
218	significance (P=0.18). There was no significant interaction effect between mid-life LE8
219	total score and sex (P=0.195) (Supplementary Table 4). Women with poor CVH
220	exhibited dCDT total scores that were, on average, 0.79 SD lower than those with
221	intermediate CVH (95% CI: -1.22, -0.35; <i>P</i> <0.001) ( <b>Supplementary Table 3</b> ). This
222	association was not observed in men. And the sex significantly influences the
223	association between mid-life CVH categories and dCDT performance (Supplementary
224	Figure 3), with a <i>P</i> value of 0.016 for interaction term.
225	Effect modification by APOE ε4 status

226 No significant interaction effect of APOE ε4 status with mid-age LE8 scores (P=0.053)

and CVH categories was observed (*P*=0.249) (**Supplementary Table 4**). There were

variations in the strength of the association of dCDT scores with LE8 total score and the CVH categories when comparing *APOE*  $\varepsilon$ 4 carriers to non-carriers (**Supplementary Figure 4**). Specifically, among *APOE*  $\varepsilon$ 4 non-carriers, an increase in mid-life LE8 total score was associated with a 0.12 SD increase in dCDT total score (95% CI: 0.03, 0.21; *P*=0.009). In contrast, *APOE*  $\varepsilon$ 4 carriers experienced a more pronounced improvement of effect size with a beta of 0.29 (95% CI: 0.11, 0.47; *P*=0.002) (**Supplementary Table 5**).

### 235 Association of mid-age LE8 scores with incident AD

An increase of one SD in the mid-life LE8 total score was associated with a 45%

237 reduction in the risk of incident AD (95% CI: 0.49, 0.87; *P*=0.003) (**Table 3**). Compared

with participants with intermediate CVH, those with the ideal CVH appeared a 53%

decreased AD risk (95% CI: 0.23, 0.98; *P*=0.045). Conversely, participants with poor

240 CVH in mid-life were observed to have a 43% increased risk of incident AD

241 (Supplementary Figure 5). For each SD increase in the mid-life LE8 behavior score,

242 there was a 46% reduction in the risk of incident AD (95% CI: 0.49, 0.83; *P*<0.001)

243 (**Supplementary Table 6**). The proportional hazards assumption was consistently

satisfied in all Cox models.

### 245 Association of dCDT scores with incident AD

Each SD increase in the dCDT total score was associated with a 49% lower risk of
incident AD (95% CI: 0.42, 0.61; *P*<0.001) (**Table 3**). The significant associations
between incident AD and domain-specific performances in all four domains under both
command and copy tasks were observed (FDR-adjusted *P*<0.001) (**Supplementary**

Table 7). Higher levels of domain-specific cognitive scores were associated with lower
hazards of developing AD during the follow-up period, with HRs ranging from 0.51 to
0.67 (FDR-adjusted *P*<0.001).</li>

#### 253 **ROC Curve Analysis**

**Figure 4** illustrates the progression of predictive performance for incident AD starting from a base model that integrated age, sex, and education level, resulting in an AUC of 0.63. By incorporating the dCDT total score into this base model, the AUC increased to 0.81. Subsequent addition of both the LE8 total score and the *APOE*  $\varepsilon$ 4 allele status to the base model each yielded AUCs of 0.69. The most comprehensive model, which included the dCDT total score, LE8 total score, and *APOE*  $\varepsilon$ 4 status with the demographic variables, reached the highest AUC of 0.84.

261

#### 262 **DISCUSSION**

Our study investigated the association of mid-age LE8 scores with dCDT performance and incident AD. The results indicated individuals with higher LE8 total score in their middle ages tend to exhibit better cognitive performance and a reduced risk of incident AD. In addition, higher mid-age LE8 health factors and lifestyle behavior scores positively correlate specific cognitive functions in older age. The ROC analysis illustrated the model containing LE8 total score, dCDT total score, and *APOE*  $\varepsilon$ 4 status achieved the highest AUC of 0.84 in predicting incident AD.

AD, as a neurodegenerative condition, may progress many years before
 noticeable symptoms occur.[32] Previous studies have underscored the importance of

272 detecting and addressing risk factors in midlife in delay and prevention of AD in later 273 years [33, 34]. Our study builds on this foundation by emphasizing the CVH in midlife as 274 a critical period for implementing intervention and prevention strategies before the 275 disease progresses significantly. Previous studies have established various methods of 276 measuring CVH in middle age and analyzed the associations between mid-age CVH 277 and AD [35, 36]. Another study discovered that mid-age Framingham Stroke Risk 278 Profile was significantly associated with memory decline [37]. More studies have used 279 LS7 to guantify CVH, and found that higher LS7 protect cognition [8, 9, 38-40]. LE8 280 incorporating eight modifiable risk factors and uses a 100-point scale for assessment, 281 providing a more comprehensive and nuanced perspective of CVH evaluation [11]. Our 282 study revealed consistent finding with a superior LE8 score in middle life was 283 associated with improved cognitive performance and a reduced AD risk.

284 Digital cognitive assessment tests are becoming widely used and hold the 285 potential to replace traditional paper-based tests as a rapid and more sensitive tool for 286 detecting early cognitive decline. Establishing the relationship between CVH and these 287 new modalities of cognitive performance is essential. A prior study that compared the 288 performance of dCDT with conventional NP test observed that the composite scores 289 built based on dCDT were superior surrogates for their corresponding NP tests [41]. 290 Specifically, lower standard errors and more significant P values were found in the 291 associations between dCDT composite scores and mild cognitive impairments compared with associations with NP tests [41]. 292

Genetic factors, particularly the presence of the *APOE* ε4 allele, are known to
 significantly and negatively influence the onset of AD [42, 43]. Our study found that

295 among APOE £4 carriers, a correlation exists between CVH condition in middle age and 296 a more pronounced cognitive decline, aligning with previously reported findings [38]. 297 APOE £4 carriers with suboptimal CVH in their middle ages tend to have a greater 298 increase in the risk of AD. Conversely, APOE £4 carriers with ideal CVH in this period 299 are likely to see a more significant reduction in AD risk. Given the significant impact 300 genetic factors, particularly the APOE  $\varepsilon$ 4 allele, on AD onset and the observed 301 correlation between mid-life CVH and cognitive decline among APOE £4 carriers, we 302 advocate for the adoption of healthy lifestyle habits and the maintenance of optimal 303 CVH from an early age for all individuals. This approach is particularly emphasized for 304 those with the APOE  $\varepsilon$ 4 allele, given their increased risk, but is beneficial universally to 305 mitigate AD risk.

306 Our study had several strengths. The FHS Offspring Cohort, being a longitudinal 307 cohort, serves as a reliable and extensive data source. It uniquely offers both 308 longitudinal LE8 measures and dCDT data, a rarity in other studies. Our study has 309 limitations in several aspects. First, the FHS Offspring cohort comprises those who are 310 non-Hispanic White from a relatively affluent town, many of whom have received a 311 college degree or above education [35]. This may lead to limitations in the 312 representability of our findings to more diverse populations. Additionally, we have a 313 relatively small number of incident AD cases during a median of 17.5 years of follow-up 314 since the middle age. The small sample size in AD poses challenges in conducting 315 robust subgroup analysis. Therefore, further studies with diverse populations and larger 316 sample sizes are warranted.

In summary, these results underline the importance of mid-life cardiovascular health in predicting cognitive outcomes and the development of AD. Our results indicated that optimal mid-age CVH is associated with enhanced cognitive function and a reduced risk of incident AD, particularly in women and those with higher AD genetic risk.

322

## 323 ACKNOWLEDGEMENTS

- 324 We express our gratitude to the participants of the Framingham Heart Study for their
- 325 commitment, acknowledging that this research could not have been conducted without
- their involvement. Additionally, we extend our thanks to the FHS researchers for their

327 sustained dedication to subject examinations over the years.

328

### 329 FUNDING

330 This work was supported by National Heart, Lung, and Blood Institute contract (N01-

HC-25195; HHSN268201500001I), and NIH grants from the National Institute on Aging

332 (AG008122, AG062109, AG068753)

333

## 334 AUTHOR CONTRIBUTIONS

- Jian Yang (Conceptualization; Methodology; Data Curation; Formal analysis;
- 336 Investigation; Writing Original Draft; Writing Review & Editing; Visualization); Huitong
- 337 Ding (Investigation; Writing Original Draft; Writing Review & Editing); Yi Li (Data

338	Curation; Writing - Review & Editing); Ting Fang Alvin Ang, Sherral Devine, Yulin Liu,
339	Wendy Qiu, Rhoda Au, and Jiantao Ma (Resources; Writing - Review & Editing; Other);
340	Chunyu Liu (Conceptualization; Methodology; Writing - Original Draft; Writing - Review
341	& Editing; Visualization; Supervision; Project administration; Funding acquisition; Other).
342	
343	CONFLICT OF INTEREST
344	Dr. Au is a scientific advisor to Signant Health and NovoNordisk, and a consultant to the
345	Davos Alzheimer's Collaborative. The other authors state that this study was carried out

- 346 without any commercial or financial affiliations that might be seen as a possible conflict
- of interest.
- 348

## 349 DATA AVAILABILITY

- 350 The data used in this study could be requested through an application to the
- 351 Framingham Heart Study (<u>https://www.framinghamheartstudy.org/fhs-for-researchers/</u>).

352

# 353 ETHICS APPROVAL AND CONSENT TO PARTICIPATE

- 354 The study's procedures and protocols received approval from the Institutional Review
- 355 Board at Boston University Medical Campus. All participants provided written informed

356 consent.

#### 358 **REFERENCE**

- 359 1. Tiwari, S., et al., Alzheimer's disease: pathogenesis, diagnostics, and 360 therapeutics. International journal of nanomedicine, 2019: p. 5541-5554. 361 2. Pase, M.P., C.L. Satizabal, and S. Seshadri, Role of Improved Vascular Health in 362 the Declining Incidence of Dementia. Stroke, 2017. **48**(7): p. 2013-2020. 363 3. Stefanowski, B., et al., Cognitive decline and dementia in women after 364 menopause: Prevention strategies. Maturitas, 2023. 168: p. 53-61. 365 Povova, J., et al., Epidemiological of and risk factors for Alzheimer's disease: a 4. 366 review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2012. 156(2): 367 p. 108-14. 368 Crous-Bou, M., et al., Alzheimer's disease prevention: from risk factors to early 5. intervention. Alzheimers Res Ther, 2017. 9(1): p. 71. 369 370 6. Norton, S., et al., Potential for primary prevention of Alzheimer's disease: an 371 analysis of population-based data. Lancet Neurol, 2014. 13(8): p. 788-94. 372 7. Han, L., et al., National Trends in American Heart Association Revised Life's 373 Simple 7 Metrics Associated With Risk of Mortality Among US Adults. JAMA 374 Netw Open, 2019. 2(10): p. e1913131. 375 8. Pase, M.P., et al., Association of Ideal Cardiovascular Health With Vascular 376 Brain Injury and Incident Dementia. Stroke, 2016. 47(5): p. 1201-6. 377 9. Zhao, Y.L., et al., Association between Life's Simple 7 and cerebrospinal fluid 378 biomarkers of Alzheimer's disease pathology in cognitively intact adults: the 379 CABLE study. Alzheimers Res Ther, 2022. 14(1): p. 74. 380 10. Guo, J., et al., Association of Life's Simple 7 with incident dementia and its 381 modification by the apolipoprotein E genotype. Alzheimers Dement, 2021. **17**(12): 382 p. 1905-1913. 383 11. Lloyd-Jones, D.M., et al., Life's Essential 8: Updating and Enhancing the 384 American Heart Association's Construct of Cardiovascular Health: A Presidential 385 Advisory From the American Heart Association. Circulation, 2022. 146(5): p. e18-386 e43. 387 12. Davis, R., et al., THink: Inferring Cognitive Status from Subtle Behaviors. Proc 388 AAAI Conf Artif Intell, 2014. 2014: p. 2898-2905.
  - 18

389	13.	Rentz, D.M., et al., Association of Digital Clock Drawing With PET Amyloid and
390		Tau Pathology in Normal Older Adults. Neurology, 2021. 96(14): p. e1844-e1854.
391	14.	Kannel, W.B., et al., An investigation of coronary heart disease in families. The
392		Framingham offspring study. Am J Epidemiol, 1979. <b>110</b> (3): p. 281-90.
393	15.	Feinleib, M., et al., The Framingham Offspring Study. Design and preliminary
394		<i>data.</i> Prev Med, 1975. <b>4</b> (4): p. 518-25.
395	16.	Benjamin, I., et al., American Heart Association Cardiovascular Genome-
396		Phenome Study: foundational basis and program. Circulation, 2015. 131(1): p.
397		100-12.
398	17.	Burgio, K.L., K.A. Matthews, and B.T. Engel, Prevalence, incidence and
399		correlates of urinary incontinence in healthy, middle-aged women. J Urol, 1991.
400		<b>146</b> (5): p. 1255-9.
401	18.	Prineas, R.J., et al., United States national prevalence of electrocardiographic
402		abnormalities in black and white middle-age (45- to 64-Year) and older (>/=65-
403		Year) adults (from the Reasons for Geographic and Racial Differences in Stroke
404		<i>Study).</i> Am J Cardiol, 2012. <b>109</b> (8): p. 1223-8.
405	19.	Jiang, C.H., F. Zhu, and T.T. Qin, Relationships between Chronic Diseases and
406		Depression among Middle-aged and Elderly People in China: A Prospective
407		<i>Study from CHARLS.</i> Curr Med Sci, 2020. <b>40</b> (5): p. 858-870.
408	20.	Carbonneau, M., Li, Y., Liu, C., Huan, T., Joehanes, R., Murabito, J., Heard-
409		Costa, N., Ma, J., & Levy, D, Abstract 13855: Epigenetic Aging Markers Mediate
410		the Association of Life's Essential Eight With Cardiovascular Disease and All-
411		Cause Mortality Journal of the American Heart Association, 2023.
412		148(Suppl_1).
413	21.	Appel, L.J., et al., A clinical trial of the effects of dietary patterns on blood
414		pressure. DASH Collaborative Research Group. N Engl J Med, 1997. 336(16): p.
415		1117-24.
416	22.	Mellen, P.B., et al., Deteriorating dietary habits among adults with hypertension:
417		DASH dietary accordance, NHANES 1988-1994 and 1999-2004. Arch Intern Med,
418		2008. <b>168</b> (3): p. 308-14.

419	23.	Kannel, W.B. and P. Sorlie, Some health benefits of physical activity. The
420		<i>Framingham Study.</i> Arch Intern Med, 1979. <b>139</b> (8): p. 857-61.
421	24.	Gomes-Osman, J., et al., Aging in the Digital Age: Using Technology to Increase
422		the Reach of the Clinician Expert and Close the Gap Between Health Span and
423		<i>Life Span.</i> Front Digit Health, 2021. <b>3</b> : p. 755008.
424	25.	Matusz, E.F., et al., Dissociating Statistically Determined Normal Cognitive
425		Abilities and Mild Cognitive Impairment Subtypes with DCTclock. J Int
426		Neuropsychol Soc, 2023. <b>29</b> (2): p. 148-158.
427	26.	Thompson, L.I., et al., Digital Clock Drawing as an Alzheimer's Disease
428		Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in
429		Older Adults. The Journal of Prevention of Alzheimer's Disease, 2023.
430	27.	Chene, G., et al., Gender and incidence of dementia in the Framingham Heart
431		Study from mid-adult life. Alzheimers Dement, 2015. 11(3): p. 310-320.
432	28.	Ahl, R.E., et al., Defining MCI in the Framingham Heart Study Offspring:
433		education versus WRAT-based norms. Alzheimer Dis Assoc Disord, 2013. 27(4):
434		p. 330-6.
435	29.	Guze, S.B., Diagnostic and statistical manual of mental disorders, (DSM-IV).
436		American Journal of Psychiatry, 1995. <b>152</b> (8): p. 1228-1228.
437	30.	McKhann, G., et al., Clinical diagnosis of Alzheimer's disease: Report of the
438		NINCDS-ADRDA Work Group* under the auspices of Department of Health and
439		Human Services Task Force on Alzheimer's Disease. Neurology, 1984. 34(7): p.
440		939-939.
441	31.	Benjamini, Y.H., Yosef, Controlling the False Discovery Rate: A Practical and
442		Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society,
443		1995. <b>Vol.57(1)</b> : p. p.289-300.
444	32.	Wolk, D.A. and J.A. Detre, Arterial spin labeling MRI: an emerging biomarker for
445		Alzheimer's disease and other neurodegenerative conditions. Curr Opin Neurol,
446		2012. <b>25</b> (4): p. 421-8.
447	33.	Vu, T.T., et al., Favorable Cardiovascular Health at Young and Middle Ages and
448		Dementia in Older Age-The CHA Study. J Am Heart Assoc, 2019. 8(1): p.
449		e009730.

450	34.	Lee, Y., et al., Systematic review of health behavioral risks and cognitive health
451		<i>in older adults.</i> Int Psychogeriatr, 2010. <b>22</b> (2): p. 174-87.
452	35.	Armstrong, N.M., et al., Associations Between Midlife (but Not Late-Life)
453		Elevated Coronary Heart Disease Risk and Lower Cognitive Performance:
454		Results From the Framingham Offspring Study. Am J Epidemiol, 2019. 188(12):
455		p. 2175-2187.
456	36.	Bleckwenn, M., et al., Impact of coronary heart disease on cognitive decline in
457		Alzheimer's disease: a prospective longitudinal cohort study in primary care. Br J
458		Gen Pract, 2017. <b>67</b> (655): p. e111-e117.
459	37.	Gupta, A., et al., Mid-life Cardiovascular Risk Impacts Memory Function: The
460		Framingham Offspring Study. Alzheimer Dis Assoc Disord, 2015. 29(2): p. 117-
461		23.
462	38.	Peloso, G.M., et al., Cardiovascular health, genetic risk, and risk of dementia in
463		<i>the Framingham Heart Study.</i> Neurology, 2020. <b>95</b> (10): p. e1341-e1350.
464	39.	Tin, A., et al., Genetic Risk, Midlife Life's Simple 7, and Incident Dementia in the
465		Atherosclerosis Risk in Communities Study. Neurology, 2022. 99(2): p. e154-
466		e163.
467	40.	Malik, R., et al., Midlife vascular risk factors and risk of incident dementia:
468		Longitudinal cohort and Mendelian randomization analyses in the UK Biobank.
469		Alzheimers Dement, 2021. <b>17</b> (9): p. 1422-1431.
470	41.	Yuan, J., et al., Association Between the Digital Clock Drawing Test and
471		Neuropsychological Test Performance: Large Community-Based Prospective
472		Cohort (Framingham Heart Study). J Med Internet Res, 2021. 23(6): p. e27407.
473	42.	Crean, S., et al., Apolipoprotein E epsilon4 prevalence in Alzheimer's disease
474		patients varies across global populations: a systematic literature review and
475		meta-analysis. Dement Geriatr Cogn Disord, 2011. 31(1): p. 20-30.
476	43.	Jefferson, A.L., et al., APOE and mild cognitive impairment: the Framingham
477		Heart Study. Age Ageing, 2015. 44(2): p. 307-11.
478		
479		

100	<b>Table 1</b> Characteristics of the 1109 r	sorticipants in the EUS Offenring cohort
400		

	I I		0	
Variable	Male (n=517)	Female (n=681)	Total (n=1198)	P value
Age at dCDT (years), mean (SD)	73.2 (6.8)	73.0 (7.0)	73.1 (6.9)	0.654
Age at last FHS exam in mid- age (years), mean (SD)	62.4 (2.1)	62.4 (2.1)	62.4 (2.1)	0.735
Education levels, No. (%)				
No high School	18 (3.5)	14 (2.1)	32 (2.7)	
High School	85 (16.4)	162 (23.8)	247 (20.6)	
Some College	119 (23.0)	231 (33.9)	350 (29.2)	< 0.001
College and	295 (57.1)	274 (40.2)	569 (47.5)	
<i>ΑΡΟΕ</i> ε4+, Νο. (%)	110 (21.3)	159 (23.3)	269 (22.5)	0.398
Number of FHS exams in mid- age <sup>a</sup> , median [IQR]	4 [3, 4]	4 [3, 4]	4 [3, 4]	0.869
Mid-age LE8 scores, mean (SD)				
Total score	64.5 (10.5)	68.9 (11.7)	67.0 (11.4)	<0.001
Behavior score	64.4 (14.0)	65.8 (14.0)	65.2 (14.0)	0.0961
Factor score	64.2 (14.5)	72.1 (16.8)	68.7 (16.3)	<0.001
CVH Categories <sup>b</sup> , No. (%)				
Intermediate	315 (60.9)	302 (44.3)	617 (51.5)	
Poor	43 (8.3)	41 (6.0)	84 (7.0)	<0.001
Ideal	159 (30.8)	338 (49.6)	497 (41.5)	
dCDT total score, mean (SD)	70.9 (23.1)	74.0 (22.4)	72.7 (22.7)	0.0197
AD, No (%)	21 (4.1)	24 (3.5)	45 (3.8)	0.740
Time-to-event from last FHS exam in mid-age <sup>c</sup> (years), median [IQR]	17.5 [12.2, 23.9]	17.4 [12.0, 24.0]	17.5 [12.1, 23.9]	0.439
Time-to-event from dCDT <sup>d</sup> (years), median [IQR]	8.9 [6.1, 9.9]	8.9 [5.6, 9.9]	8.9 [5.7, 9.9]	0.313

<sup>481</sup> <sup>a</sup>The number of FHS core exams, where the information collected is utilized to calculate

482 mid-age LE8 scores.

<sup>483</sup> <sup>b</sup>These categories were derived based on LE8 total score: Ideal (>70), Intermediate

484 (50–70), and Poor (<50).

485 <sup>c</sup>The time in years from the last mid age FHS exam in to the onset of AD.

<sup>486</sup> <sup>d</sup>The time in years from the time of dCDT examination to the onset of AD.

487 **Table 2**. Association of dCDT total score with LE8 total score and CVH categories

Main Predictor	Beta	95% CI	SE	P value
LE8 total score	0.16	(0.08, 0.24)	0.04	<0.001
CVH categories				
Intermediate	Ref		-	-
Poor	-0.36	(-0.67, -0.05)	0.16	0.024
Ideal	0.18	(0.01, 0.34)	0.08	0.036

488 The association was examined by linear regression model adjusting for age at dCDT

489 examination, delta age, sex, and education levels.

- 491 **Table 3**. Association of incident AD with LE8 total score, CVH categories, and dCDT
- 492 total score

Main Predictor	HR	95% CI	P value
LE8 total score <sup>a</sup>	0.65	(0.49, 0.87)	0.003
CVH categories <sup>b</sup>			
Intermediate	Ref	-	-
Poor	1.43	(0.59, 3.47)	0.433
Ideal	0.47	(0.23, 0.98)	0.045
dCDT total score <sup>c</sup>	0.51	(0.42, 0.61)	<0.001

<sup>a</sup>The association of AD with mid-age LE8 total score (z-score) was examined by adjusting for age at last included FHS exam, sex, and education levels.

<sup>495</sup> <sup>b</sup>The association of AD and CVH categories (intermediate was used as the reference group)

496 was examined by adjusting for age at last included FHS exam, sex, and education levels.

497 <sup>c</sup>The association analyses of AD and dCDT total score (z-score) was examined by adjusting for

498 age at dCDT, sex, and education levels.

- 500 **Figure 1.** Study design. Middle age was defined as the age range from 45 to 65 years.
- 501 Approximately 72% of participants in their middle age were assessed between Exam 5
- and Exam 8 (from 1991 to 2008). We calculated the mean LE8 scores from all exams
- 503 attended by a participant during their middle age. The statistical analyses included: 1.
- 504 Association analyses of the baseline dCDT with the mean mid-age LE8 scores,
- adjusting for age at baseline dCDT, sex, and education, and the age difference between
- 506 dCDT and the last LE8 measurement. 2. Association analyses of the mean mid-age
- 507 LE8 scores with incident AD during a median follow up of 17.5 years, adjusted for age
- at the last LE8 measurement, sex, and education. 3. Association analyses of the
- 509 baseline dCDT with incident AD during a median follow up of 8.9 years, adjusted for age
- 510 at baseline dCDT, sex, and education.



#### Statistical models

- 1. Linear Regression: dCDT score = LE8 score + covariates
- 2. Cox Regression: AD = LE8 score + covariates
- 3. Cox Regression: AD = dCDT score + covariates

- 512 **Figure 2**. Association of CVH with dCDT total score and incident AD (n=1,198). A
- 513 scatter plot with standardized mid-age LE8 total scores on the x-axis and standardized
- 514 dCDT total scores on the y-axis, representing individual data points that are color-coded
- 515 according to three levels of CVH: poor (light blue), intermediate (blue), and ideal (dark
- 516 blue). A trend line is shown, indicating a positive correlation between LE8 total scores
- and dCDT total scores with statistically significant (*P*<0.0001). The distribution of LE8
- 518 total scores and dCDT total cores is illustrated by histograms.



521 **Figure 3.** ROC curve plot that compares the AD prediction performance of five different

522 models. Model 1: AD ~ Age + Sex + Education; Model 2: AD ~ LE8 total score + Age +

523 Sex + Education; Model 3: AD ~ dCDT total score + Age + Sex + Education; Model 4:

524 AD ~ APOE + Age + Sex + Education; Model 5: AD ~ LE8 total score + dCDT total

525 score + APOE + Age + Sex + Education





Statistical models

- 1. Linear Regression: dCDT score = LE8 score + covariates
- 2. Cox Regression: AD = LE8 score + covariates
- 3. Cox Regression: AD = dCDT score + covariates



